Glucagon intranasal - Eli Lilly/Locemia Solutions

Drug Profile

Glucagon intranasal - Eli Lilly/Locemia Solutions

Alternative Names: AMG504-1; Dry powder intranasal - Locemia Solutions; Dry-mist intranasal glucagon - Locemia Solutions; Glucagon - Locemia Solutions; IN glucagon - Locemia Solutions; LY 900018

Latest Information Update: 04 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AMG Medical
  • Developer Eli Lilly; Locemia Solutions
  • Class Antihypoglycaemics; Pancreatic hormones
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypoglycaemia
  • No development reported Common cold

Most Recent Events

  • 17 Jun 2016 Eli Lilly and Locemia terminate a phase I trial for Hypoglycaemia in USA and Canada due to delivery device malfunctioning (Intranasal) before June 2016 (NCT02806960)
  • 24 May 2016 No development reported - Phase-I for Common cold in Canada and USA (Intranasal)
  • 10 Feb 2016 Phase-III development is ongoing in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top